Minimizing Sample Failure Rates for Clinical Tumor Samples

This research article explores the efficacy of SLIMamp technology in reducing sample failure rates in challenging clinical tumor samples. The study demonstrates that 77% of previously unreportable samples yielded clinically actionable variants, highlighting the potential of amplicon-based NGS tests in improving diagnostic outcomes for cancer patients. The findings support the use of innovative sequencing methods to enhance the quality of genomic testing in oncology.